Jun. 24, 2025 — GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) approved an updated label for its positron emission tomography (PET) imaging agent Vizamyl (flutemetamol F 18 injection) for beta-amyloid detection.
PET Imaging
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.
Jun. 24, 2025 — GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) approved an updated label ...
June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics ...
June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...
Digital technology is opening remarkable opportunities for clinical positron emission tomography (PET) about which ...
June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research ...
May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...
Jan. 30, 2025 – Earlier this month, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer’s ...
Precision can have an enormous impact on patients. From diagnosis to patient monitoring (see “How Digital PET/CT Can ...
Jan. 24, 2025 —The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear ...
Jan. 8, 2025 – The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer’s Association have ...
Nov. 25, 2024 — GE HealthCare has announced it is woking with Peter MacCallum Cancer Centre in Melbourne, Australia, to ...
PET is getting ready to venture outside oncology, cardiology and mainstream neurology. High on the list of new clinical ...
Oct. 21, 2024 — Siemens Healthineers recently received Food and Drug Administration clearance for two new features in ...
Aug. 28, 2024 – AC Immune SA recently announced that its partner Life Molecular Imaging (LMI) has received Fast Track ...
July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...
Analog is approximate. Digital is specific. Therein lies the fundamental difference between digital PET and its analog ...
July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...
July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...
July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...
June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...
June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...